118 related articles for article (PubMed ID: 32673260)
1. Decentralized, Community-Based Hepatitis C Point-of-Care Testing and Direct-Acting Antiviral Treatment for People Who Inject Drugs and the General Population in Myanmar: Protocol for a Feasibility Study.
Draper BL; Pedrana A; Howell J; Yee WL; Htay H; Aung KS; Shilton S; Kyi KP; Naing W; Hellard M
JMIR Res Protoc; 2020 Jul; 9(7):e16863. PubMed ID: 32673260
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of the CT2 study: A 'one-stop-shop' for community-based hepatitis C testing and treatment in Yangon, Myanmar.
Draper BL; Htay H; Pedrana A; Yee WL; Howell J; Pyone Kyi K; Naing W; Sanda Aung K; Markby J; Easterbrook P; Bowring A; Aung W; Sein YY; Nwe N; Myint KT; Shilton S; Hellard M
Liver Int; 2021 Nov; 41(11):2578-2589. PubMed ID: 34153155
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of a decentralized, community-based "one-stop-shop" hepatitis C testing and treatment program in Yangon, Myanmar.
Win TM; Draper BL; Palmer A; Htay H; Sein YY; Shilton S; Kyi KP; Hellard M; Scott N
JGH Open; 2023 Nov; 7(11):755-764. PubMed ID: 38034058
[TBL] [Abstract][Full Text] [Related]
4. Patients' access to and acceptance of community-based hepatitis C testing and treatment in Myanmar: A mixed-method study.
Yee WL; Bowring A; Draper B; O'Keefe D; Htay H; Myint KT; Aung HWP; Win YY; Sein YY; Mary M; Lin A; Pedrana A; Hellard M
PLOS Glob Public Health; 2023; 3(6):e0000902. PubMed ID: 37327249
[TBL] [Abstract][Full Text] [Related]
5. Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting.
Read P; Lothian R; Chronister K; Gilliver R; Kearley J; Dore GJ; van Beek I
Int J Drug Policy; 2017 Sep; 47():209-215. PubMed ID: 28587943
[TBL] [Abstract][Full Text] [Related]
6. Feasibility of antiretroviral treatment monitoring in the era of decentralized HIV care: a systematic review.
Pham MD; Romero L; Parnell B; Anderson DA; Crowe SM; Luchters S
AIDS Res Ther; 2017 Jan; 14(1):3. PubMed ID: 28103895
[TBL] [Abstract][Full Text] [Related]
7. Initial outcomes of integrated community-based hepatitis C treatment for people who inject drugs: Findings from the Queensland Injectors' Health Network.
Morris L; Smirnov A; Kvassay A; Leslie E; Kavanagh R; Alexander N; Davey G; Williams O; Gilks C; Najman J
Int J Drug Policy; 2017 Sep; 47():216-220. PubMed ID: 28666635
[TBL] [Abstract][Full Text] [Related]
8. Point-of-care hepatitis C testing from needle and syringe programs: An Australian feasibility study.
Williams B; Howell J; Doyle J; Thompson AJ; Draper B; Layton C; Latham N; Bramwell F; Membrey D; Mcpherson M; Roney J; Stoové M; Hellard ME; Pedrana A
Int J Drug Policy; 2019 Oct; 72():91-98. PubMed ID: 31129023
[TBL] [Abstract][Full Text] [Related]
9. A systematic review and meta-analysis of community and primary-care-based hepatitis C testing and treatment services that employ direct acting antiviral drug treatments.
Radley A; Robinson E; Aspinall EJ; Angus K; Tan L; Dillon JF
BMC Health Serv Res; 2019 Oct; 19(1):765. PubMed ID: 31660966
[TBL] [Abstract][Full Text] [Related]
10. Uptake of direct acting antiviral therapies for the treatment of hepatitis C virus among people who inject drugs in a universal health-care system.
Butler K; Larney S; Day CA; Burns L
Drug Alcohol Rev; 2019 Mar; 38(3):264-269. PubMed ID: 30548702
[TBL] [Abstract][Full Text] [Related]
11. Treatment adherence and support for people who inject drugs taking direct-acting antiviral therapy for hepatitis C infection.
Read P; Gilliver R; Kearley J; Lothian R; Cunningham EB; Chronister KJ; Dore GJ
J Viral Hepat; 2019 Nov; 26(11):1301-1310. PubMed ID: 31299127
[TBL] [Abstract][Full Text] [Related]
12. The impact of universal access to direct-acting antiviral therapy on the hepatitis C cascade of care among individuals attending primary and community health services.
Traeger MW; Pedrana AE; van Santen DK; Doyle JS; Howell J; Thompson AJ; El-Hayek C; Asselin J; Polkinghorne V; Membrey D; Bramwell F; Carter A; Guy R; Stoové MA; Hellard ME;
PLoS One; 2020; 15(6):e0235445. PubMed ID: 32603349
[TBL] [Abstract][Full Text] [Related]
13. Patients' experience of accessing hepatitis C treatment through the Myanmar national hepatitis C treatment program: a qualitative evaluation.
Draper B; Yee WL; Bowring A; Naing W; Kyi KP; Htay H; Howell J; Hellard M; Pedrana A
BMC Health Serv Res; 2024 Jan; 24(1):80. PubMed ID: 38229074
[TBL] [Abstract][Full Text] [Related]
14. Integrated models of care for people who inject drugs and live with hepatitis C virus: A systematic review.
Socías ME; Karamouzian M; Parent S; Barletta J; Bird K; Ti L
Int J Drug Policy; 2019 Oct; 72():146-159. PubMed ID: 31147142
[TBL] [Abstract][Full Text] [Related]
15. Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade.
Scott N; Doyle JS; Wilson DP; Wade A; Howell J; Pedrana A; Thompson A; Hellard ME
Int J Drug Policy; 2017 Sep; 47():107-116. PubMed ID: 28797497
[TBL] [Abstract][Full Text] [Related]
16. Association between rapid utilisation of direct hepatitis C antivirals and decline in the prevalence of viremia among people who inject drugs in Australia.
Iversen J; Dore GJ; Catlett B; Cunningham P; Grebely J; Maher L
J Hepatol; 2019 Jan; 70(1):33-39. PubMed ID: 30367897
[TBL] [Abstract][Full Text] [Related]
17. Feasibility and acceptability of adherence support for direct acting antiviral therapy for hepatitis C in a low-threshold primary health-care opioid agonist treatment program.
Chronister KJ; Lothian R; Gilliver R; Kearley J; Read P
Drug Alcohol Rev; 2019 Feb; 38(2):185-189. PubMed ID: 30761640
[TBL] [Abstract][Full Text] [Related]
18. Understanding real-world adherence in the directly acting antiviral era: A prospective evaluation of adherence among people with a history of drug use at a community-based program in Toronto, Canada.
Mason K; Dodd Z; Guyton M; Tookey P; Lettner B; Matelski J; Sockalingam S; Altenberg J; Powis J
Int J Drug Policy; 2017 Sep; 47():202-208. PubMed ID: 28619394
[TBL] [Abstract][Full Text] [Related]
19. The Parasol Protocol: An Implementation Science Study of HIV Continuum of Care Interventions for Gay Men and Transgender Women in Burma/Myanmar.
Wirtz AL; Naing S; Clouse E; Thu KH; Mon SHH; Tun ZM; Baral S; Paing AZ; Beyrer C
JMIR Res Protoc; 2017 May; 6(5):e90. PubMed ID: 28526661
[TBL] [Abstract][Full Text] [Related]
20. Modeling indicates efficient vaccine-based interventions for the elimination of hepatitis C virus among persons who inject drugs in metropolitan Chicago.
Echevarria D; Gutfraind A; Boodram B; Layden J; Ozik J; Page K; Cotler SJ; Major M; Dahari H
Vaccine; 2019 May; 37(19):2608-2616. PubMed ID: 30962092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
